JNCE Jounce Therapeutics Inc

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer of Jounce, will present at two upcoming investor conferences:

• Baird 2017 Global Healthcare Conference at 12:15 p.m. ET on Wednesday, September 6, 2017 in New York, NY
• 2017 Wells Fargo Healthcare Conference at 8:15 a.m. ET on Thursday, September 7, 2017 in Boston, MA

A live webcast of each presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following each presentation.

About Jounce TherapeuticsJounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 2 trial. For more information, please visit www.jouncetx.com.

Media Contact:
Katie Engleman
Pure Communications, Inc.
(910) 509-3977  
kengleman@purecommunications.com

Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com